RP 3467
Alternative Names: RP-3467Latest Information Update: 26 Aug 2024
At a glance
- Originator Repare Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Adenosine triphosphatase inhibitors; DNA polymerase theta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 19 Aug 2024 Repare Therapeutics plans a phase I POLAR trial for Solid tumours (Late-stage disease, Monotherapy, Combination therapy, Second-line therapy or greater, Metastatic disease) in USA (NCT06560632)
- 08 Jan 2024 Pharmacodynamics data from preclinical studies in Cancer released by Repare Therapeutics
- 15 Nov 2023 Pharmacodynamics data from preclinical studies in Cancer released by Repare Therapeutics